{
    "clinical_study": {
        "@rank": "144585", 
        "arm_group": {
            "arm_group_label": "CM082 tablet", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation starting from 50 mg, oral once a day, 28 day cycles. Number of Cycles: until disease progression or unacceptable toxicity develops."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and\n      Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors."
        }, 
        "brief_title": "Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Cancer", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and\n      Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors. After the\n      maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion\n      cohort of ~20 advanced renal cell carcinoma patients will be enrolled to further\n      characterize the safety and tumor response by CT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor\n             malignancy that is not responsive to standard therapies or for which there is no\n             effective therapy.\n\n          -  Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  No immuno deficiency.\n\n          -  Adequate organ system function, defined as follows:\n\n               -  Absolute neutrophil count (ANC) \u22651.5 x 10**9/L\n\n               -  Platelets \u2265100 x 10**9/L\n\n               -  Hemoglobin \u226510 g/dL\n\n               -  Total bilirubin \u22641.5 times the upper limit of normal (ULN)\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22641.5x the\n                  upper limit of normal (ULN) if no liver involvement or \u22642.5x the upper limit of\n                  normal with liver involvement.\n\n               -  Creatinine \u2264 1.5 x ULN.\n\n          -  At least 4 weeks or 5 half-life after receiving cancer therapy (i.e., chemotherapy,\n             radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or\n             tumor embolization.\n\n          -  Willingness and ability to comply with trial and follow-up procedures.\n\n          -  Ability to understand the nature of this trial and give written informed consent.\n\n        Exclusion Criteria:\n\n          -  Not recovered from prior anti-cancer therapy or surgery.\n\n          -  Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks.\n\n          -  Concomitant use of drugs with a risk of causing prolonged corrected QT interval\n             and/or Torsades de Pointes.\n\n          -  Patients with a history of intolerance to, or significant toxicity with, VEGFR\n             tyrosine kinase inhibitor(s) (TKI).\n\n          -  Females who are pregnant or breastfeeding.\n\n          -  Those in reproductive ages who refuse to use contraception.\n\n          -  Those with concurrent condition(e.g. psychological, neuronal, cardiovascular,\n             respiratory conditions or infections) that in the investigator's opinion would\n             jeopardize compliance with the protocol.\n\n          -  Patients with known central nervous system (CNS) metastases.\n\n          -  Presence of active gastrointestinal (GI) disease or other condition that will\n             interfere significantly with the absorption, distribution, metabolism, or excretion\n             of CM082 (X-82).\n\n          -  Patients with known GI disorders such as vomiting, diarrhea.\n\n          -  Patients who are hepatitis B virus positive.\n\n          -  Drug abuser."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863485", 
            "org_study_id": "CM082-CA-I-001", 
            "secondary_id": "2013L00579\u30012013L00581"
        }, 
        "intervention": {
            "arm_group_label": "CM082 tablet", 
            "description": "After the MTD or the optimal biological dose is identified, an expansion cohort of ~20 advanced renal cell carcinoma patients will be enrolled and treated with CM082 tablets.", 
            "intervention_name": "CM082 Tablet, expansion cohort", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "advanced cancer", 
        "lastchanged_date": "May 23, 2013", 
        "location": {
            "contact": {
                "email": "cancergcp@163.com", 
                "last_name": "Lin Yang, M.D.", 
                "phone": "011 86 10 8778 8118"
            }, 
            "contact_backup": {
                "email": "cancergcp@163.com", 
                "last_name": "Yan Song, B.S.", 
                "phone": "011 86 10 8778 8118"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "investigator": {
                "last_name": "Lin Yang, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Safety, Tolerability, and Pharmacokinetic Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China", 
        "other_outcome": {
            "description": "clinical tumor response by computed tomography (CT) after treatment with CM082 tablets given as a single agent.", 
            "measure": "Preliminary biological activity", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_contact": {
            "email": "cancergcp@163.com", 
            "last_name": "Lin Yang, M.D", 
            "phone": "011 86 10 8778 8118"
        }, 
        "overall_contact_backup": {
            "email": "cancergcp@163.com", 
            "last_name": "Yan Song, B.S.", 
            "phone": "011 86 10 8778 8118"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing", 
            "last_name": "Jin-Wan Wang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the Maximum Tolerated Dose in Chinese patients with advanced solid tumors.", 
            "measure": "Maximum Tolerated Dose", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863485"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetic (PK) parameters such as Cmax and Tmax of CM082 tablets given as a single agent to Chinese cancer patients.", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Challenge MediTech, Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Challenge MediTech, Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}